Transcatheter Valve Replacement Research for Aortic Regurgitation Has Expanded Rapidly Over 20 Years
Research on transcatheter aortic valve replacement for aortic regurgitation has moved from a narrow technical question to a broad, increasingly collaborative field. A bibliometric and visualized analysis spanning 2004 through 2023 identified 2,189 publications across 200 journals, with both publication volume and citation frequency rising steadily over time. The pattern reflects a mature and expanding literature rather than a transient burst of interest. In practical terms, the field now sits at the intersection of device engineering, procedural refinement, and long-horizon clinical follow-up.
The clinical pressure behind that expansion is easy to understand. Aortic regurgitation remains a difficult valve disease to solve with transcatheter technology because the annulus, leaflet anatomy, and anchoring conditions differ from the calcified aortic stenosis population that drove the earliest TAVR experience. For that reason, research output in this area tends to cluster around questions of procedural feasibility, device design, and patient selection rather than around a single settled therapeutic algorithm.
One sentence captures the field’s momentum: publication counts kept climbing while citation activity rose with them.
Leading Investigators, Journals, and Countries Shaped the Field’s Direction
Several names recur at the center of the literature. Leon, Martin B; Webb, John G; and Rodes-Cabau, Josep emerged as the most prolific scholars in the dataset, reflecting their sustained influence on the development and evaluation of transcatheter valve therapy. Their presence in the literature also signals how closely this research area has been tied to high-volume structural heart programs and iterative device innovation.
Journal distribution showed a similar concentration. Catheterization and Cardiovascular Interventions produced the highest output among journals indexed in the analysis, reinforcing the procedural and interventional identity of the topic. Geographically, the United States, Germany, and Italy led publication output, while the 10 most influential institutions were all based in European and American countries. That concentration suggests that technical capability, device access, and research infrastructure still shape where the evidence base is generated.
The dominance of a limited set of countries and institutions matters for interpretation of the literature. It means the field’s most visible insights are being produced in systems with advanced imaging, catheterization expertise, and strong links between engineering and clinical cardiology. For a disease that affects patients across health systems with very different resources, that imbalance leaves open questions about generalizability, feasibility, and access.
Keyword Clusters Point to Three Persistent Research Priorities
The keyword analysis examined 169 terms appearing more than 20 times and identified a clear structure in the research conversation. Three themes stood out: procedural innovation, patient-specific risk assessment, and long-term outcome evaluation. Those priorities reflect the unresolved biology and mechanics of treating aortic regurgitation without open surgery. Unlike stenotic valves, regurgitant valves often provide less calcific anchoring, so procedural success depends heavily on device fit, deployment stability, and imaging-guided planning.
This is where the field has become more sophisticated. Early-stage work focused on whether transcatheter replacement could be done at all in patients with AR. More recent studies have moved toward which devices perform best, which anatomic features predict success or failure, and how to preserve durability after implantation. The bibliometric pattern captures that shift by showing a growing emphasis on translational questions rather than purely descriptive device reports.
Long-term outcome evaluation deserves special attention because structural heart interventions are judged not only by procedural success but by valve durability, symptom relief, and downstream clinical events. Aortic regurgitation can impose chronic volume overload, ventricular remodeling, and progressive heart failure if left untreated or undertreated. Any transcatheter strategy must therefore do more than seal the lesion in the catheterization lab; it must produce durable hemodynamic correction that remains stable over time.
Device Engineering and Bioengineering Now Drive the Next Phase
The analysis points to operative techniques, valve device systems, and bioengineering technologies as likely future research directions. That trajectory fits the clinical demands of the disease. A device intended for aortic regurgitation must address anchoring, sealing, and positional stability in a setting where native anatomy is often less forgiving than in calcific stenosis. Engineering advances may therefore matter as much as operator technique, because even a well-executed procedure can fail if the prosthesis cannot reliably engage the annulus.
Bioengineering also has a larger role here than in many other procedural fields. Material design, frame geometry, leaflet dynamics, and delivery-system refinement all influence how well a transcatheter valve can perform in regurgitant anatomy. The research agenda now clearly extends beyond procedural adaptation and into device redesign tailored to the disease substrate.
One clear bedside consequence follows from that reality: patient selection will remain central until device performance becomes more predictable across anatomies.
The Evidence Base Is Growing Faster Than the Long-Term Data Set
The study’s conclusion is cautious for good reason. While the bibliometric map shows a robust and accelerating literature, it also exposes the limits of the evidence structure itself. Large randomized trials and long-term follow-up data remain relatively limited compared with the breadth of publication activity. A field can generate many papers and still lack definitive answers about durability, comparative effectiveness, and outcomes in diverse populations.
For clinicians, that gap is not academic. Structural heart teams need to know which patients with aortic regurgitation are most likely to benefit from transcatheter therapy, how often reintervention may be needed, and whether early technical success translates into better survival or quality of life. Bibliometric growth does not answer those questions, but it does show where the field is putting its intellectual energy.
The study also illustrates an important feature of modern cardiovascular research: innovation moves fastest when engineering, imaging, and clinical cardiology are aligned. Yet the same concentration of expertise that accelerates progress can also narrow the patient populations studied. Broader translational work will be needed to determine whether advances developed in specialized centers can be deployed safely and effectively in more diverse clinical settings.
Translational Priorities Will Decide Whether the Field Matures
The most important message is not simply that the literature is growing. It is that the field has moved from proof-of-concept toward a more demanding phase in which safety, accessibility, and long-term benefit will determine whether TAVR for aortic regurgitation becomes a dependable option rather than a niche solution. Future work will need to integrate procedural science with outcomes research, because technical feasibility alone cannot establish durable clinical value.
That challenge is especially pressing for a disease that can progress silently before producing heart failure symptoms and ventricular dysfunction. If transcatheter therapy is to reduce the global burden of aortic regurgitation, it must be supported by reproducible device performance, broader geographic participation in research, and follow-up that extends beyond the immediate procedural window.
The bibliometric record makes one point unmistakable: the field is advancing, but the decisive evidence for long-term clinical adoption still has to catch up with the pace of publication.